The UK stock market has been experiencing some turbulence, with the FTSE 100 index recently closing lower due to weak trade data from China, highlighting challenges in global economic recovery. Despite these broader market pressures, certain stocks are currently priced below their estimated value, presenting potential opportunities for investors who focus on fundamentals and long-term growth prospects.
Name
Current Price
Fair Value (Est)
Discount (Est)
Oxford Biomedica (LSE:OXB)
£8.04
£15.28
47.4%
Motorpoint Group (LSE:MOTR)
£1.345
£2.64
49%
Informa (LSE:INF)
£8.896
£17.03
47.8%
Ibstock (LSE:IBST)
£1.366
£2.50
45.4%
Hochschild Mining (LSE:HOC)
£5.815
£11.30
48.5%
Fintel (AIM:FNTL)
£2.02
£3.78
46.5%
CAB Payments Holdings (LSE:CABP)
£0.66
£1.29
49%
Barratt Redrow (LSE:BTRW)
£3.689
£7.18
48.6%
Anglo Asian Mining (AIM:AAZ)
£2.78
£5.21
46.7%
Advanced Medical Solutions Group (AIM:AMS)
£2.22
£4.32
48.7%
Let’s take a closer look at a couple of our picks from the screened companies.
Overview: ASA International Group PLC operates as a microfinance institution in Asia and Africa, with a market cap of £195 million.
Operations: The company’s revenue segments include $40.66 million from South Asia, $65.82 million from East Africa, $65.29 million from West Africa, and $34.92 million from South East Asia.
Estimated Discount To Fair Value: 11.3%
ASA International Group appears undervalued based on cash flows, trading at £1.95 against a fair value estimate of £2.20. Despite high volatility, its earnings have grown by 121.7% in the past year and are projected to grow annually by 20.83%, outpacing the UK market’s 13.9%. Recent leadership changes, including appointing Geert Embrechts as CFO, aim to bolster long-term growth strategies amidst strong client demand and loan portfolio expansion forecasts for 2025 exceeding expectations of US$48.3 million profit.
LSE:ASAI Discounted Cash Flow as at Jan 2026
Overview: Burberry Group plc, along with its subsidiaries, operates in the manufacturing, retail, and wholesale of luxury goods under the Burberry brand across regions including Asia Pacific, Europe, the Middle East, India, Africa, and the Americas with a market cap of £4.78 billion.
Operations: The company’s revenue is primarily derived from its Retail/Wholesale segment, which accounts for £2.34 billion, complemented by £66 million from Licensing.
Estimated Discount To Fair Value: 31.1%
Burberry Group is trading at £13.31, significantly below its estimated fair value of £19.31, indicating potential undervaluation based on cash flows. Despite a forecasted mid-single-digit revenue decline for 2026, the company expects growth in the latter half of the year. Recent leadership changes aim to enhance strategic execution and customer engagement, while extending its eyewear licensing agreement with EssilorLuxottica through 2035 supports long-term brand strength and innovation initiatives.
LSE:BRBY Discounted Cash Flow as at Jan 2026
Overview: Oxford Biomedica plc is a contract development and manufacturing organization specializing in delivering therapies globally, with a market cap of £970.85 million.
Operations: The company’s revenue is primarily derived from Development Services (£56.49 million), Manufacturing Services (£75.19 million), and Licences, Milestones and Royalties (£5.05 million).
Estimated Discount To Fair Value: 47.4%
Oxford Biomedica is trading at £8.04, significantly below its estimated fair value of £15.28, highlighting potential undervaluation based on cash flows. The company is expected to achieve profitability within three years with earnings projected to grow substantially each year. Revenue growth forecasts exceed the UK market average, and a very high return on equity is anticipated in three years. Recent executive changes include Robert Ghenchev’s departure from the board following his exit from Novo Holdings US.
LSE:OXB Discounted Cash Flow as at Jan 2026
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:ASAI LSE:BRBY and LSE:OXB.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com